Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ritesh Patil

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Journal of General Internal Medicine|March 3, 2009
Visual hallucinations in a patient with adult onset acid maltase deficiency disorderRitesh Patil, Jack L Depriest
Resuscitation|November 21, 2009
The Code Blue 2-min drillJack L Depriest, Ritesh Patil, Trupti Patil
Journal of General Internal Medicine|May 4, 2011
Staphylococcus lugdunensis native tricuspid valve endocarditis: a case report and review of literatureRitesh Patil, Trupti Patil, K M Anwar Hussain
Journal of General Internal Medicine|November 25, 2010
Mycobacterium porcinum peritonitis in a patient on continuous ambulatory peritoneal dialysisRitesh Patil, Trupti Patil, Louis Schenfeld, et al.
Cancer|September 17, 2010
Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02Jarrod P Holmes, Guy T Clifton, Ritesh Patil, et al.
Anti-Cancer Drugs|September 3, 2013
MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinical modelsJuan J Gu, Francisco J Hernandez-Ilizaliturri, Cory Mavis, et al.
Journal of the American College of Surgeons|February 2, 2010
Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II clinical trialRitesh Patil, Guy T Clifton, Jarrod P Holmes, et al.
Cancer|August 30, 2008
Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02Jarrod P Holmes, Jeremy D Gates, Linda C Benavides, et al.
Cancer|October 13, 2011
Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02Elizabeth A Mittendorf, Guy T Clifton, Jarrod P Holmes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2009
The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02Linda C Benavides, Jeremy D Gates, Mark G Carmichael, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Journal of General Internal Medicine|March 3, 2009
Visual hallucinations in a patient with adult onset acid maltase deficiency disorderRitesh Patil, Jack L Depriest
Resuscitation|November 21, 2009
The Code Blue 2-min drillJack L Depriest, Ritesh Patil, Trupti Patil
Journal of General Internal Medicine|May 4, 2011
Staphylococcus lugdunensis native tricuspid valve endocarditis: a case report and review of literatureRitesh Patil, Trupti Patil, K M Anwar Hussain
Journal of General Internal Medicine|November 25, 2010
Mycobacterium porcinum peritonitis in a patient on continuous ambulatory peritoneal dialysisRitesh Patil, Trupti Patil, Louis Schenfeld, et al.
Cancer|September 17, 2010
Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02Jarrod P Holmes, Guy T Clifton, Ritesh Patil, et al.
Anti-Cancer Drugs|September 3, 2013
MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinical modelsJuan J Gu, Francisco J Hernandez-Ilizaliturri, Cory Mavis, et al.
Journal of the American College of Surgeons|February 2, 2010
Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II clinical trialRitesh Patil, Guy T Clifton, Jarrod P Holmes, et al.
Cancer|August 30, 2008
Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02Jarrod P Holmes, Jeremy D Gates, Linda C Benavides, et al.
Cancer|October 13, 2011
Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02Elizabeth A Mittendorf, Guy T Clifton, Jarrod P Holmes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2009
The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02Linda C Benavides, Jeremy D Gates, Mark G Carmichael, et al.
Pageof 1